Q4 2024 Organogenesis Holdings Inc Earnings Call Transcript
Key Points
- Organogenesis Holdings Inc (ORGO) reported a 27% increase in net revenue for the fourth quarter, exceeding the high end of their guidance range.
- The company achieved a gross profit margin of 75.5% in Q4, up from 72.1% the previous year.
- Operating income for the fourth quarter was $10.2 million, a significant improvement from an operating loss of $1.3 million in the previous year.
- Organogenesis Holdings Inc (ORGO) ended the year with $136.2 million in cash and no outstanding debt obligations, reflecting a strong financial position.
- The company is on track for a BLA submission for its Renu product by the end of 2025, which could represent a transformational opportunity in the pain management market.
- The delay in the implementation of LCDs has created ambiguity and disruption in customer behavior, leading to a challenging operating environment in early 2025.
- The company anticipates a very competitive first half of 2025 due to the delayed LCD implementation, which may impact revenue and demand.
- There was some attrition in the salesforce during the quarter, although it was not significant.
- The company faces uncertainty regarding the conversion of products to those on the covered list, impacting revenue projections.
- PuraPly, a significant component of the Advanced Wound Care business, is not currently on the covered list, which could affect its usage and revenue.
Please stand by.
Welcome, ladies and gentlemen to the fourth quarter and fiscal year 2024, earnings conference call for Organogenesis Holdings Inc. (Operator Instructions)
Before we begin, I would like to remind everyone that our remarks today may contain forward-looking statements that are based on the current expectations of management and involve inherent risk and uncertainties, that can cause actual results to differ materially from those indicated, including the risk and uncertainties described in the company's filings with the Securities and Exchange Commission, including Item 1A (Risk Factors) of the company's most recent annual report and is subsequently filed quarterly reports.
You are cautioned not to place undue reliance upon any forward-looking statements, which may speak only as the date made. Although it may voluntarily do so from time to time, the company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
This
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
